Literature DB >> 8427773

DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

M Karlsson1, B Boeryd, J Carstensen, B Kågedal, A T Bratel, S Wingren.   

Abstract

In 82 patients with stage III malignant melanoma, the primary tumours were investigated by DNA flow cytometry. The tumours were classified as DNA diploid (n = 36), tetraploid (n = 11) and aneuploid (n = 35). By univariate analysis a significant correlation with post-recurrence survival was found for time to first metastasis, DNA-ploidy and S-phase fraction. By multivariate analysis, significant prognostic variables were found to be the time to first metastasis (P = 0.006), and ploidy (P = 0.011). Patients with diploid melanomas and a long recurrence-free interval had a median post-recurrence survival time of 45 months compared to 18 months in patients with DNA aneuploid tumours and an early recurrence. The S-phase could be estimated in 47 primary melanomas and was found to be a significant prognostic variable (P = 0.017). The median survival was 45 months for patients with melanomas with a S-phase fraction below 5%, and 19 months for melanomas with S-phase above 10%. The prognostic value of the S-phase remained significant even after adjustment for recurrence-free interval and DNA ploidy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427773      PMCID: PMC1968202          DOI: 10.1038/bjc.1993.23

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle.

Authors:  H Baisch; W Göhde; W A Linden
Journal:  Radiat Environ Biophys       Date:  1975-06-13       Impact factor: 1.925

2.  Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer.

Authors:  O Stål; S Wingren; J Carstensen; L E Rutqvist; L Skoog; C Klintenberg; B Nordenskjöld
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02

3.  Prognostic factors in cutaneous malignant melanoma in stage I. A clinical, morphological and multivariate analysis.

Authors:  J Eldh; B Boeryd; L E Peterson
Journal:  Scand J Plast Reconstr Surg       Date:  1978

4.  Flow cytofluorometric DNA analyses of metastases of human malignant melanomas.

Authors:  J Hansson; B Tribukait; R Lewensohn; U Ringborg
Journal:  Anal Quant Cytol       Date:  1982-06

5.  Single cell DNA cytophotometry in clinical stage I malignant melanoma. Relationship to prognosis.

Authors:  C Lindholm; P A Hofer; H Jonsson
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

6.  DNA flow cytometry in the prognosis of primary malignant melanoma.

Authors:  D Bartkowiak; J Schumann; F J Otto; A Lippold; H Drepper
Journal:  Oncology       Date:  1991       Impact factor: 2.935

7.  A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

8.  Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator.

Authors:  P Rosenberg; S Wingren; E Simonsen; O Stàl; B Risberg; B Nordenskjöld
Journal:  Gynecol Oncol       Date:  1989-10       Impact factor: 5.482

9.  DNA aneuploidy and low S-phase fraction as favourable prognostic signs in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; S Asko-Seljavaara; K Franssila
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  3 in total

1.  Prognostic significance in malignant melanoma of nuclear DNA content measured by a microfluorimetric method.

Authors:  Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

2.  DNA index and S phase fraction in uveal malignant melanomas.

Authors:  W G Hodge; A J Duclos; G Rocha; E Antecka; M G Baines; C Corriveau; S Brownstein; J Deschenes
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

3.  DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; S Wingren
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.